具有小比例CCA成分的混合性肝细胞癌-胆管癌（cHCC-CCA）病例与HCC病例之间的无复发生存（RFS）预后是否存在差异仍不清楚。我们的目的是探讨具有小比例CCA成分的cHCC-CCA与HCC之间RFS预后的差异。前瞻性招募接受MRI和手术的肝恶性肿瘤患者。所有cHCC-CCA患者根据CCA成分的比例分为不同组。主要终点是无复发生存期。采用Cox回归分析和Kaplan-Meier生存分析来调查和比较RFS预后。共纳入164例cHCC-CCA和271例HCC病例。 CCA成分≥10%的cHCC-CCA病例与HCC病例之间的RFS预后没有显着差异（对数等级p=≥0.169）。一些有利于 HCC 的主要 MR 特征没有显着差异，例如非边缘 APHE（85.7% vs. 81.5%，p = 0.546）、非外周冲洗（80.0% vs. 84.1%，p = 0.534）和增强包膜（ 62.9% vs. 45.4%，p = 0.051）。此外，CCA成分≥10%的cHCC-CCA与HCC之间的一些临床病理学结果没有显着差异（均p>0.05）。RFS预后、有利于HCC的主要MRI特征和临床病理结果没有显着差异CCA 成分为 < 10% 的 cHCC-CCA 与 HCC 之间。因此，我们建议，病理诊断 CCA 成分少于 10% 的 cHCC-CCA 在临床环境中可按 HCC 治疗。© 2024。亚太肝脏研究协会。

Whether there are differences in recurrence-free survival (RFS) prognosis between combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA) cases with a small proportion of CCA components and HCC cases remains unknown. We aim to investigate the differences in RFS prognosis between cHCC-CCAs with a small proportion of CCA components and HCCs.Patients with malignant liver neoplasms who underwent MRI and surgery were prospectively recruited. All cHCC-CCA patients were divided into different groups according to the ratio of CCA components. The primary end point was recurrence-free-survival. Cox regression analysis and Kaplan-Meier survival analysis was used to investigate and compare RFS prognosis.One hundred sixty-four cHCC-CCA cases and 271 HCC cases were enrolled. There was no significant difference in RFS prognosis between cHCC-CCA cases with a CCA component of < 10% and HCC cases (log rank p = 0.169). There were no significant differences in some major HCC-favoring MR features, such as nonrim APHE (85.7% vs. 81.5%, p = 0.546), nonperipheral washout (80.0% vs. 84.1%, p = 0.534), and enhancing capsule (62.9% vs. 45.4%, p = 0.051) between them. In addition, some clinicopathological findings had no significant differences between cHCC-CCAs with a CCA component of < 10% and HCCs (all p > 0.05).There were no significant differences in RFS prognosis, major HCC-favoring MRI features, and clinicopathological findings between cHCC-CCAs with a CCA component of < 10% and HCCs. Therefore, we suggest that cHCC-CCAs with pathological diagnosis of less than 10% of CCA components may be treated as HCCs in clinical setting.© 2024. Asian Pacific Association for the Study of the Liver.